Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review.
Rev Inst Med Trop Sao Paulo
; 61: e12, 2019 Feb 14.
Article
em En
| MEDLINE
| ID: mdl-30785566
ABSTRACT
Chronic Hepatitis C relapse after liver transplantation can lead to graft failure within a short time period. The high efficacy and good safety profile of direct-acting antivirals has led to consensual recommendations for using interferon-free treatment after liver transplantation. However, pegylated interferon may still be required for genotype 3 non-responders. We treated a liver graft recipient with grade 1 fibrosis in the biopsy with daclatasvir and sofosbuvir for 12 weeks. He did not respond and progressed to grade 3 fibrosis. Lacking other options, we obtained a sustained virological response with pegylated interferon, ribavirin and sofosbuvir for 12 weeks. The combination of pegylated interferon, ribavirin and sofosbuvir is a viable option after the failure of direct acting antivirals in economically disadvantaged countries.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Polietilenoglicóis
/
Ribavirina
/
Interferon-alfa
/
Hepatite C Crônica
/
Sofosbuvir
/
Interferon alfa-2
Tipo de estudo:
Guideline
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article